Pfizer (PFE) Receivables (2009 - 2026)

Pfizer has disclosed Receivables across 18 years of filings, most recently posting $12.6 billion for Q1 2026.

• In Q1 2026, Receivables rose 6.25% year-over-year to $12.6 billion; the TTM figure through Mar 2026 stood at $12.6 billion (up 6.25% YoY), while the FY2025 annual figure was $11.9 billion, up 3.59% from the prior year.
• Receivables grew to $12.6 billion in Q1 2026, from $11.9 billion in the prior quarter.
• Over the last five years, Receivables for PFE reached as high as $16.2 billion in Q4 2022 and fell as low as $10.2 billion in Q3 2023.
• The 5-year median for Receivables is $11.9 billion (2025), against an average of $12.5 billion.
• Annual changes were most pronounced in 2022 — Receivables surged 39.98% — and 2023, when it slumped 33.68%.
• A 5-year view of Receivables shows it stood at $11.0 billion in 2022, then grew by 5.61% to $11.6 billion in 2023, then fell by 0.89% to $11.5 billion in 2024, then gained by 3.59% to $11.9 billion in 2025, then grew by 5.99% to $12.6 billion in 2026.
• According to Business Quant data, Receivables over the past three periods registered $12.6 billion, $11.9 billion, and $14.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.